Table 2.
Treatment Administered to Acromegaly Patients Classified by Types
| Acromegaly Types |
P Value | |||
|---|---|---|---|---|
| 1 | 2 | 3 | ||
| Surgery, n | 137 | 51 | 89 | .006a |
| 1 | 121 (88) | 38 (74.5) | 63 (71) | |
| 2 | 16 (12) | 12 (23.5) | 18 (20) | |
| 3 or more | 0 (0) | 1 (2) | 8 (9) | |
| Radiotherapy, n | 139 | 53 | 87 | .02a |
| Irradiated cases | 23 (16.5) | 9 (17) | 20 (23) | |
| Medical treatments, n | 89 | 32 | 62 | |
| None | 4 (4.5) | 1 (3.1) | 1 (1.6) | .32b |
| Somatostatin analogs (SRLs) | 71 (80) | 27 (84) | 58 (93.5) | .02b |
| D2DAs | 47 (53) | 12 (37.5) | 36 (58) | .62b |
| PEG | 11 (12) | 6 (19) | 17 (27) | .02b |
| Combined | 53 (59) | 16 (50) | 47 (77) | .01b |
| SRLs, D2DA, PEG1 | .006b | |||
| 1 group medication | 46 (52) | 18 (56) | 23 (37) | |
| 2 groups medications | 34 (38) | 12 (37.5) | 26 (42) | |
| 3 groups medications | 5 (6) | 1 (3) | 12 (19) | |
| No. of combined treatments received2 | 145 | 55 | 89 | <.0001a |
| 1 | 56 (39) | 20 (36) | 22 (25) | |
| 2 | 38 (26) | 15 (27) | 17 (19) | |
| 3 | 30 (21) | 12 (22) | 21 (24) | |
| 4 | 14 (10) | 7 (13) | 18 (20) | |
| 5 or more | 7 (5) | 1 (2) | 11 (12) | |
| Follow-up | ||||
| GH, ng/mL | 2.2 (1.0–5.1) | 1.8 (0.6–4.3) | 3.7 (1.1–8.6) | .02c |
| Nadir GH after OGTT, ng/mL | 1.0 (0.2–2.9) | 0.8 (0.4–2.6) | 1.5 (0.6–5.0) | .11c |
| GH after OGTT, n | 65 | 30 | 31 | .04e |
| >0.4 ng/mL | 44 (68) | 20 (67) | 27 (87) | |
| IGF-1 (ng/mL) | 221 (134–324)d | 234 (145–369)d | 370 (193–637) | <.0001c |
| IGF-1 levels (%ULN) | 99 (81–117) | 93 (78–107) | 137 (94–180) | .04b |
| IGF-1 levels, n | 129 | 53 | 81 | .004a |
| Not elevated | 88 (68) | 33 (62) | 39 (48) | |
Data are expressed as number (percent) or median (interquartile range), unless described otherwise.
a
Linear by linear association χ2.
b
Fisher exact χ2 test.
c
Kruskal-Wallis H test.
d
P value <.05, Mann-Whitney U test between type 1 or 2 vs type 3.
e
P value from Fisher's χ2 exact test.
1
Number of medical treatments used throughout follow-up, not necessarily together (SRLs and/or D2DAs and/or PEG).
2
Number of treatments used throughout follow-up (SRLs, and/or D2DAs, and/or PEG, and/or number of surgeries, and/or radiotherapy).